Literature DB >> 182507

Effect of some phosphodiesterase inhibitors on central dopamine mechanisms.

B B Fredholm, K Fuxe, L Agnati.   

Abstract

The effect of five phosphodiesterase (PDE) inhibitors (papaverine, IBMX, theophyllamine, dipyridamol and M & B 22,948) was studied on adenylate cyclase and on cyclic nucleotide phosphodiesterase activities in extracts of rat caudate nucleus. For comparison the effect on DA turnover and on turning behaviour in rats with unilateral lesions of the nigro-neostriatal DA nerurons was studied. Cyclic AMP PDE was inhibited by papaverine, dipyridamol, IBMX, M & B 22,948 and theophyllamine in that order of potency. Cylcic GMP PDE was inhibited by IBMX, papaverine, M & B 22,948 and theophyllamine, but not by dipyridamol. Basal adenylate cyclase washigher if assayed in the presence of papaverine or dipyridamol than if theophyllamine or IBMX was present. The degree of stimulation caused by DA was not significantly influenced by the PDE inhibitors. Papaverine and dipyridamol enhanced DA disappearance in the caudate nucleus and the tuberculum accumbens, but not in the median eminence. Caffeine had no significant effect. Papaverine (1-28 mg/kg) had no signigicant effect on L-dopa (5 mg/kg)-induced turning, and actually inhibited turning induced by the combination of L-dopa (10 mg/kg) and atropine (5 mg/kg). The other four PDE inhibitors all potentiated L-dopa-induced turning. Theophyllamine (20 mg/kg) and IBMX (5 mg/kg) even caused turning when given alone. The data are compatible with the opinion that PDE inhibition leads to an enhanced effect of DA in the caudate nucleus. However, the results also demonstrate that several of the PDE inhibitors have effects on central DA mechanisms that are difficult to explain solely on the basis of PED inhibition.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182507     DOI: 10.1016/0014-2999(76)90198-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Intramembrane receptor-receptor interactions: a novel principle in molecular medicine.

Authors:  K Fuxe; M Canals; M Torvinen; D Marcellino; A Terasmaa; S Genedani; G Leo; D Guidolin; Z Diaz-Cabiale; A Rivera; L Lundstrom; U Langel; J Narvaez; S Tanganelli; C Lluis; S Ferré; A Woods; R Franco; L F Agnati
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 2.  Receptor-receptor interactions as an integrative mechanism in nerve cells.

Authors:  M Zoli; L F Agnati; P B Hedlund; X M Li; S Ferré; K Fuxe
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

3.  Endogenous adenosine as a modulator of hippocampal acetylcholine release.

Authors:  R Jackisch; H Strittmatter; L Kasakov; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

4.  Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.

Authors:  S Ferre; G von Euler; B Johansson; B B Fredholm; K Fuxe
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

5.  Methylxanthine-induced attenuation of pecking in chickens.

Authors:  M R Zarrindast; T Nasir
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

6.  Oxpentifylline in Parkinson's disease.

Authors:  R B Godwin-Austen; J A Twomey; G Hanks; J Higgins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-04       Impact factor: 10.154

7.  Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses.

Authors:  M Herrera-Marschitz; M Casas; U Ungerstedt
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

8.  Adenosine receptors and behavioral actions of methylxanthines.

Authors:  S H Snyder; J J Katims; Z Annau; R F Bruns; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

Review 9.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

Review 10.  Purinergic Signalling in Parkinson's Disease: A Multi-target System to Combat Neurodegeneration.

Authors:  Adrián Tóth; Zsófia Antal; Dániel Bereczki; Beáta Sperlágh
Journal:  Neurochem Res       Date:  2019-05-04       Impact factor: 3.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.